Bellerophon Therapeutics (BLPH) Is a Great Choice for 'Trend' Investors, Here's Why
- Bellerophon Therapeutics (BLPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
- 03/28/2023
|
Here's Why Momentum in Bellerophon Therapeutics (BLPH) Should Keep going
- Bellerophon Therapeutics (BLPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
- 03/10/2023
|
How to Find Cheap Penny Stocks to Make Money Trading
- Use these tips for finding cheap penny stocks to buy The post How to Find Cheap Penny Stocks to Make Money Trading appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/06/2023
|
5 Hot Penny Stocks Exploding After News This Week
- Hot penny stocks with news to watch this week. The post 5 Hot Penny Stocks Exploding After News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/05/2023
|
Bellerophon (BLPH) Receives FDA Acceptance to Reduce Study Size
- Bellerophon's (BLPH) proposal to reduce the size of its ongoing phase III REBUILD study of INOpulse in fibrotic Interstitial Lung Disease gets accepted by the FDA. Stock up.
- 09/28/2022
|
Bellerophon to Present at the H.C. Wainwright BioConnect 2022 Conference
- WARREN, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Naseem Amin, M.D., Chairman of Bellerophon's Board of Directors, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, being held virtually January 10-13, 2022.
- 01/10/2022
|
Bellerophon Therapeutics Stock (BLPH): Why The Price Jumped
- The stock price of Bellerophon Therapeutics Inc (NASDAQ: BLPH) increased by 34.6% in the previous trading session. This is why it happened.
- 12/20/2021
|
These Biotech Penny Stocks Exploded Today, Here's Why
- Which biotech penny stocks are you watching right now? The post These Biotech Penny Stocks Exploded Today, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/17/2021
|
Bellerophon Therapeutics (BLPH) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
- After losing some value lately, a hammer chart pattern has been formed for Bellerophon Therapeutics (BLPH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
- 12/01/2021
|
Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
- WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held September 13-15, 2021.
- 09/07/2021
|
Why Entera Bio, Orphazyme, Bellerophon Are Moving Today
- Entera Bio Ltd. (NASDAQ: ENTX), Orphazyme A/S (NASDAQ: ORPH) and Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) are among the biggest biopharma movers Wednesday.
- 06/23/2021
|
8 Hot Biotech Penny Stocks For Your July 2021 Watch List
- Current & Former Penny Stocks To Watch Before July The post 8 Hot Biotech Penny Stocks For Your July 2021 Watch List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/23/2021
|
Bellerophon to Present at the Jefferies Virtual Healthcare Conference
- WARREN, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the Jefferies Virtual Healthcare Conference, being held June 1-4, 2021.
- 05/27/2021
|
Bellerophon Appoints Naseem Amin, M.D. as Chairman of its Board of Directors
- Dr. Amin Has Served as an Independent Director Since 2015 and Succeeds Jonathan Peacock Following Mr. Peacock's Retirement from the Company's Board Dr. Amin Has Served as an Independent Director Since 2015 and Succeeds Jonathan Peacock Following Mr. Peacock's Retirement from the Company's Board
- 05/26/2021
|
Bellerophon Provides Clinical Program Update and Reports First Quarter 2021 Financial Results
- WARREN, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2021.
- 05/11/2021
|
Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2020 Financial Results
- WARREN, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the fourth quarter and year ended December 31, 2020.
- 03/11/2021
|
Bellerophon to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
- WARREN, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference, being held January 11-14, 2021.
- 01/04/2021
|
Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease
- WARREN, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the first patient has been enrolled in its REBUILD Phase 3 registrational clinical study evaluating INOpulse®, a pulsed inhaled nitric oxide therapy, as a potential treatment for fibrotic interstitial lung disease (fILD).
- 12/01/2020
|
Here is What Hedge Funds Think About Bellerophon Therapeutics, Inc. (BLPH)
- Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an individual investor's stock selection process, as it may offer great insights of how the brightest minds of the finance industry feel about specific stocks. After all, these people have access to smartest analysts and expensive data/information sources that individual investors can't match. So should one consider investing in Bellerophon Therapeutics, Inc. (NASDAQ:BLPH)? The smart money sentiment can provide an answer to this question.
- 11/28/2020
|
Bellerophon Therapeutics Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse® for the Treatment of COVID-19
- WARREN, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the independent Data Monitoring Committee (DMC) has completed its pre-specified interim analysis from the first 100 patients randomized in the Phase 3 COViNOX study of INOpulse® for the treatment of COVID-19.
- 11/23/2020
|
Bellerophon to Present at the H.C. Wainwright 6th Annual Israel Conference
- WARREN, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 6th Annual Israel Conference.
- 11/11/2020
|
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2020 Financial Results
- WARREN, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today provided a clinical program update and reported financial results for the third quarter ended September 30, 2020.
- 11/05/2020
|
Bellerophon to Present Results from its Phase 2 iNO-PF Study of INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease at Upcoming Scientific Conferences
- WARREN, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, announced today that data from its Phase 2 randomized, double-blind, placebo-controlled clinical study (iNO-PF) of INOpulse® for the treatment of fibrotic Interstitial Lung Disease patients at risk for pulmonary hypertension will be presented at the American Thoracic Society Interstitial Lung Disease Mini Symposia and the 2020 Pulmonary Fibrosis Foundation Meeting.
- 10/29/2020
|
Bellerophon Appoints Cardiopulmonary Disease Expert Wassim Fares, M.D., MSCR, as Chief Medical Officer
- WARREN, N.J., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, announced today that it has appointed Wassim Fares, M.D., MSCR, as Chief Medical Officer. “We are thrilled to welcome Wassim, a seasoned industry leader, to Bellerophon to lead our clinical development at such an important time for the company,” said Fabian Tenenbaum, Chief Executive Officer of Bellerophon. “Wassim’s deep cardiopulmonary disease expertise as a pulmonologist and principal clinical trial investigator will prove critical to Bellerophon as we advance our two late-stage INOpulse® programs in Pulmonary Hypertension associated with Pulmonary Fibrosis (PH-PF) and COVID 19, as well as our other clinical-stage programs in sarcoidosis and chronic obstructive pulmonary disease.”Dr. Fares is a board-certified pulmonologist and intensive care specialist with over 20 years of experience as a physician, principal investigator, associate professor, and pharmaceutical industry executive. Most recently, Dr. Fares was Senior Medical Director at Janssen Pharmaceutical Company and a member of Janssen’s Pulmonary Hypertension therapeutic area development leadership team where he led developments across a broad range of potential indications, including fostering the design and execution of multiple Phase 1 through Phase 3 pivotal registration trials. Prior to Janssen, he consulted on clinical trial strategy for Actelion (Janssen/J&J), Bayer, Gilead, and United Therapeutics. Previously, Dr. Fares served in increasingly senior roles at Yale University, most recently as Director, a nationally-accredited Pulmonary Vascular Disease Center.“I am excited to join the Bellerophon team and lead the clinical development of the Company’s promising INOpulse therapy program,” said Dr. Fares. “The compelling positive results from Bellerophon’s Phase 2 PH-PF trial as well as the patient outcomes observed in the Company’s completed COVID-19 Expanded Access Program, highlight INOpulse’s potential to improve outcomes for patients suffering from a number of pulmonary conditions. I look forward to supporting the Company in further advancing the ongoing COVID-19 COViNOX Phase 3 trial and initiating the Phase 3 REBUILD study in PH-PF.”Dr. Fares completed his post-graduate fellowship program in Pulmonary Disease and Critical Care Medicine at the University of North Carolina and his residency in Internal Medicine at St. Vincent Charity Medical Center. He earned medical and undergraduate degrees from the American University of Beirut, and a master’s degree in clinical research from the University of North Carolina.About Bellerophon Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and infectious diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.Forward-looking Statements Any statements in this press release about Bellerophon’s future expectations, plans and prospects, including statements about the clinical development of its product candidates, regulatory actions with respect to the Company’s clinical trials and expectations regarding the sufficiency of the Company’s cash balance to fund clinical trials, operating expenses and capital expenditures, and other statements containing the words “anticipate,” “believe,” “continue,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary or interim results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, the FDA’s substantial discretion in the approval process, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and in subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent Bellerophon’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.Contacts At W2O Group: At LifeSci Advisors: Julie NormartBrian Ritchie (559) 974-3245(212) 915-2578 jnormart@w2ogroup.com britchie@lifesciadvisors.com
- 08/11/2020
|
Bellerophon Provides Clinical Program Update and Reports Second Quarter 2020 Financial Results
- WARREN, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today provided a clinical program update and reported financial results for the second quarter ended June 30, 2020.“Bellerophon has achieved significant clinical and regulatory progress advancing our development program for the INOpulse® inhaled nitric oxide therapy,” said Fabian Tenenbaum, Chief Executive Officer of Bellerophon. “We are pleased to have treated the first patient with INOpulse in our COViNOX Phase 3 clinical trial for the treatment of COVID-19 and are excited to work with leading hospitals across the U.S. to enroll patients as expeditiously as possible. The trial initiation follows highly encouraging preliminary data generated from 180 hospitalized COVID-19 patients treated under our recently completed Emergency Expanded Access Program (EAP).” “Turning to our Pulmonary Fibrosis program, we have recently completed our End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) to align on study design and endpoints and look forward to initiating our pivotal Phase 3 REBUILD trial of INOpulse in Pulmonary Hypertension associated with Pulmonary Fibrosis (PH-PF),” continued Mr. Tenenbaum. “Importantly, results from Cohort 1 of the Phase 2 Study were published in the August 2020 edition of the peer-reviewed CHEST journal and the results from Cohort 2 are being presented at the upcoming American Thoracic Society (ATS) virtual conference.” “Our strong balance sheet, enhanced by our recently closed $59.0 million from public and registered direct offerings, provides us with the resources necessary to efficiently advance our INOpulse development program and achieve our planned clinical milestones,” concluded Mr. Tenenbaum.Clinical Program Highlights:COVID-19 (Coronavirus) * COViNOX Phase 3 Study: Bellerophon announced that the first patient has been treated in the Company’s Phase 3 clinical study of INOpulse inhaled nitric oxide (iNO) therapy for the treatment of COVID-19. The Phase 3 randomized, placebo-controlled COViNOX study will evaluate the efficacy and safety of the investigational INOpulse therapy in patients diagnosed with COVID-19 who require supplemental oxygen. The COViNOX protocol utilizes an adaptive design and aims to enroll up to 500 patients with COVID-19 who will be treated with either INOpulse or placebo at major U.S. hospitals. The primary endpoint will assess the proportion of subjects that had respiratory failure or mortality, which should allow the trial to serve as a registrational study for potential approval. Bellerophon has also applied for federal funding, through the Biomedical Advanced Research and Development Authority and the National Institutes of Health, to support the clinical study. * Emergency Expanded Access: Under the recently completed EAP, 180 patients at 18 hospitals across the U.S. received treatment with INOpulse for COVID-19 under emergency expanded access granted by the FDA. The program allowed INOpulse to be used for the treatment of specific patients with COVID-19 under the care and supervision of their physician. Preliminary data demonstrated a 73.0% recovery rate and 6.3% mortality rate at day 14 from treatment initiation. Importantly, INOpulse was well-tolerated with no safety concerns related to the therapy observed by the treating physicians.PH-PF * REBUILD Phase 3 Study: Bellerophon successfully completed its End-of-Phase 2 meetings with the FDA and finalized key elements of its Phase 3 REBUILD registrational study (iNO-PF Cohort 3) of INOpulse for the treatment of PH-PF. The REBUILD study will enroll 300 PH-PF patients who will be treated with either INOpulse or placebo. The primary endpoint is change in moderate to vigorous physical activity (MVPA). The Company expects to initiate the REBUILD study in the second half of 2020. If approved, INOpulse would become the first therapy to treat a broad PH-PF population that includes patients at low-, intermediate- and high-risk of pulmonary hypertension. * iNO-PF Phase 2 Study: Bellerophon reported positive top-line results from its Phase 2 randomized, double-blind, placebo-controlled clinical study (iNO-PF) of INOpulse for the treatment of PH-PF. Subjects treated with INOpulse (iNO30 or iNO45) maintained their activity levels, including MVPA, while subjects on placebo deteriorated. Subjects treated with the higher dose of iNO45 chronically over four months demonstrated clinically and statistically significant improvement in MVPA of 14 minutes per day, representing a 20% improvement (p=0.02). Improvements in MVPA were supported by benefits in other activity parameters, as well as two patient reported questionnaires. The University of California, San Diego Shortness of Breath Questionnaire improved by 5 points and the St. George’s Respiratory Questionnaire (SGRQ) total score improved by 3 points, with the Activity and Impacts domains improving by 5 and 6 points, respectively. An anchoring analysis between MVPA and the SGRQ Activity domain established a minimally important difference for MVPA of 4.8 minutes per day.The results from Cohort 1 of the iNO-PF study were published in the August 2020 edition of the peer-reviewed CHEST journal. These results established the safety of the iNO30 dose and confirmed the potential for INOpulse to provide clinically meaningful benefits in levels of daily activity in this patient population.The results from Cohort 2 of the iNO-PF study are being presented as an e-Poster, available from August 5, 2020 to November 10, 2020, at the 2020 ATS virtual conference. These results demonstrated the safety and efficacy of the iNO45 dose and established the dose and endpoints for the pivotal REBUILD Phase 3 study.Pulmonary Hypertension-Sarcoidosis (PH-Sarc) * Phase 2 Clinical Study: Bellerophon is conducting a Phase 2 dose escalation study in PH-Sarc. The safety and efficacy study is assessing the acute hemodynamic benefit of INOpulse via right heart catheterization. PH-Sarc is an unmet medical need with a median survival of approximately five years after diagnosis. Similar to PH-PF and PH-ILD, PH-Sarc cannot be treated with currently available systemic vasodilators.Corporate Update: * In April 2020, the Company closed a registered direct offering for total gross proceeds of approximately $15.3 million, before deducting placement agent fees and offering expenses. * In May 2020, the Company closed a public offering of common stock and a concurrent registered direct offering for total gross proceeds of approximately $43.7 million, before deducting placement agent fees and offering expenses. * In June 2020, the Company was added to the Russell 3000® and Microcap® Indexes.Second Quarter Ended June 30, 2020 Financial ResultsFor the three months ended June 30, 2020, the Company reported an operating loss of $5.8 million, compared to $4.2 million in the three months ended June 30, 2019.For the three months ended June 30, 2020, the Company reported a net loss of $3.8 million, or $(0.51) per basic and diluted share, compared to a net loss of $4.1 million, or $(0.90) per basic and diluted share, for the three months ended June 30, 2019. Net loss for the three months ended June 30, 2020 included $2.1 million of tax income from the sale of the New Jersey state 2018 net operating losses and an expense of $0.2 million due to a change in fair value of common stock warrant liability, as compared to an income of $0.7 million for the three months ended June 30, 2019.Research and development expenses for the three months ended June 30, 2020 were $3.5 million, compared to $2.6 million in the prior year period. The increase was primarily due to increased activities related to the development of INOpulse.General and administrative expenses for the three months ended June 30, 2020 were $2.3 million, compared to $1.6 million in the prior year period. The increase was primarily due to higher consulting fees.Six Months Ended June 30, 2020 Financial ResultsFor the six months ended June 30, 2020, the Company reported an operating loss of $9.9 million, compared to $8.6 million in the six months ended June 30, 2019. For the six months ended June 30, 2020, the Company reported a net loss of $8.8 million, or $(1.44) per basic and diluted share, compared to a net loss of $4.9 million, or $(1.10) per basic and diluted share, in the six months ended June 30, 2019. Net loss for the six months ended June 30, 2020 included an expense of $1.1 million due to a change in fair value of the Company’s common stock warrant liability, as compared to an income of $2.3 million for the six months ended June 30, 2019.Research and development expenses for the six months ended June 30, 2020 were $5.7 million, compared to $4.9 million in the prior year period. The increase was primarily due to increased activities related to the development of INOpulse.General and administrative expenses for the six months ended June 30, 2020 were $4.2 million, compared to $3.6 million in the prior year period. The increase was primarily due to higher consulting fees.Balance Sheet As of June 30, 2020, the Company had cash and cash equivalents of $59.3 million, compared to $9.9 million at December 31, 2019. In the second quarter of 2020, Bellerophon closed a public offering of common stock and two registered direct offerings, with gross proceeds of approximately $59.0 million.About Bellerophon Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and infectious diseases.
- 08/05/2020
|
DAVENPORT & Co LLC Invests $1.35 Million in Bellerophon Therapeutics Inc (NASDAQ:BLPH)
- DAVENPORT & Co LLC purchased a new position in Bellerophon Therapeutics Inc (NASDAQ:BLPH) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 107,150 shares of the biotechnology company’s stock, valued at approximately $1,345,000. Other institutional investors have also bought and sold shares of the […]
- 08/01/2020
|
Galera Phase 2 Trial, And Other News: The Good, Bad And Ugly Of Biopharma
- Galera completed enrollment for its Phase 1b/2a clinical trial of avasopasem manganese or GC4419. Albireo enrolled the first patient in its Phase 3 clinical trial of Odevixibat.
- 07/15/2020
|
Bellerophon Therapeutics Announces Publication of Cohort 1 of iNO-PF Phase 2/3 Study in the CHEST Journal and Participation in Webinar to Discuss Clinical Results
- Patients Treated with INOpulse® Demonstrated Improved Physical Activity Compared to Placebo Live Webinar with Study Investigators on Thursday, July 16th, from 4:00-5:00 pm EDT.
- 07/15/2020
|
Bellerophon Therapeutics Announces First Patient Treated in Phase 3 Clinical Study of INOpulse® Inhaled Nitric Oxide Therapy for COVID-19
- WARREN, N.J., July 13, 2020 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and.
- 07/13/2020
|
Bellerophon Therapeutics Added to Russell 3000® and Microcap® Indexes
- Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious lung diseases, today announced that the company has been added to the Russell 3000® and Microcap® Indexes at the conclusion of the Russell indexes annual reconstitution, effective upon the U.S. market open today. Annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of May 8, 2020, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000 Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index, as well as the appropriate growth and value style indexes.
- 06/29/2020
|
Is Bellerophon Therapeutics, Inc. (BLPH) A Good Stock To Buy?
- At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]
- 06/04/2020
|
Alan Fournier Adds 4 Stocks to Portfolio
- Guru releases 1st-quarter portfolio Continue reading...
- 05/29/2020
|
Bellerophon Therapeutics Announces Closing of $43.7 Million Public Offering of Common Stock and Concurrent Registered Direct Offering and Full Exercise of Option to Purchase Additional Shares
- Bellerophon intends to use the net proceeds from the Offerings, together with its current cash and cash equivalents, for funding its ongoing clinical trials, working capital needs and other general corporate purposes. A total of 3,365,384 shares of common stock were issued in the Offerings, which includes the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $13.00 per share. Jefferies LLC acted as sole book-running manager for the Underwritten Offering.
- 05/22/2020
|
8 Biotechs Tapping Secondary Markets for $3 Billion
- Company stocks drop on dilution, but monies could benefit shareholders down the line Continue reading...
- 05/19/2020
|
Bellerophon Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Registered Direct Offering
- WARREN, N.J., May 19, 2020 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced the pricing of offerings for an aggregate of.
- 05/19/2020
|
The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 18)
ADC Therapeutics SA (NYSE:...
- 05/19/2020
|
Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock
- All of the shares in the offering are to be sold by Bellerophon. Bellerophon also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the number of shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. Bellerophon expects to use the net proceeds from this offering, together with its existing cash and cash equivalents, for funding its ongoing clinical trials, for working capital and general corporate purposes.
- 05/18/2020
|
Company News for May 12, 2020
- Companies In The News Are:
- 05/12/2020
|
Bellerophon Provides Clinical Program Update and Reports First Quarter 2020 Financial Results
- WARREN, N.J., May 11, 2020 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), (“Bellerophon” or the “Company”) a clinical-stage biotherapeutics company focused on developing.
- 05/11/2020
|
Bellerophon Therapeutics Announces FDA Clears Initiation of Phase 3 Study for INOpulse® Inhaled Nitric Oxide Therapy to Treat COVID-19
- WARREN, N.J., May 11, 2020 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing.
- 05/11/2020
|
Global Pulmonary Hypertension Industry Analysis 2016-2024: Pipeline, Epidemiology, Competitive Analysis, Drug Sales and Shares - ResearchAndMarkets.com
|
Bellerophon Therapeutics to Participate in COVID-19 Panel at Maxim Group’s Infectious Disease Virtual Conference
- WARREN, N.J., May 04, 2020 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary.
- 05/04/2020
|
Stocks To Watch: Jobs Report, Virtual Conferences And Blue Chips On Tap
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 05/02/2020
|
LVS, INO among premarket gainers
- CounterPath (NASDAQ:CPAH) +91% on Q4 update.Borqs Technologies (NASDAQ:BRQS) +22% on launching mobile smart tracking cloud solution.Immunomedics (NASDAQ:IMMU) +34% as FDA gave approval to its treatmen
- 04/23/2020
|
20 Healthcare Stocks Moving In Thursday's Pre-Market Session
- Gainers
• Immunomedics, Inc. (NASDAQ:IMMU) stock rose 31.29% to $28.87 during Thursday's pre-market session. The most recent rating by H.C. Wainwright, on Apr 23, is at...
- 04/23/2020
|
These experimental drugs may help keep COVID-19 patients off ventilators
- Several experimental therapies being tested as treatments for COVID-19 patients who are severely ill with COVID-19 aim to reduce reliance on mechanical...
- 04/17/2020
|
ROKU, CCL among premarket gainers today
- Sonnet BioTherapeutics Holdings (NASDAQ:SONN) +100%.MEI Pharma (NASDAQ:MEIP) +71% on license deal for blood cancer candidate.NantKwest (NASDAQ:NK) +39% being with ImmunityBio on active discussions wit
- 04/14/2020
|
31 Stocks Moving in Tuesday's Pre-Market Session
- Gainers
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares rose 66% to $8.20 in pre-market trading.
Tiziana Life Sciences PLC (NASDAQ: TLSA) shares rose 44.8% to $4.46...
- 04/14/2020
|
Piper Sandler softens view on Cronos Group in premarket analyst action
- Axsome Therapeutics (NASDAQ:AXSM) initiated with an Outperform rating and a $95 (58% upside) price target at Cowen and Company.Bellerophon Therapeutics (NASDAQ:BLPH) initiated with a Buy rating at Bro
- 04/14/2020
|
Covid-19: Could Bellerphon Therapeutics’ INOpulse Help Address Hospital Ventilator Shortage?
- Last year, according to the World Economic Forum, 77,000 new ventilators were enough to meet the market demand worldwide. For context, this month alone, New York City predicts a need for an extra 30,000 machines.COVID-19’s impact has stretched hospital resources to almost breaking point, but micro-cap Bellerophon Therapeutics (BLPH) might just have a solution to mitigate against the lack of ventilators. Accordingly, the stock has shot up 113% year-to-date.But H.C. Wainwright’s Andrew Fein believes the story is only beginning. Fein reiterated a Buy on Bellerophon, along with a $30 price target, which implies an impressive 168% upside from current levels. (To watch Fein’s track record, click here)Bellerophon has been granted Emergency Expanded Access for INOpulse for the treatment of COVID-19. INOpulse is a small and portable nitric oxide delivery system, which has demonstrated it can reduce viral load as well as prevent virus replication in SARS-CoV.One COVID-19 patient has already been treated and discharged from hospital and the focus now turns to the availability of units, costs, and further studies. A Phase 3 trial assessing INOpulse in the treatment of pulmonary hypertension associated with pulmonary fibrosis (PH-PF) patients is expected to begin sometime in 2Q20.Although there are other nitric oxide delivery systems available, if proven successful, INOpulse could significantly reduce the load on hospitals. Due to the unit’s compact size and potential to address the earlier pulmonary stage of COVID-19, patients who would otherwise need the help of a ventilator, could possibly be treated away from hospital settings.Fein said, “In speaking with management, the approximately hundreds of available units are currently in the process of being allocated, with potential manufacturing needs to be reassessed in the future. Importantly, we note the company remains in ongoing dialogue with the government, while we specifically highlight that the possibility of BARDA funding exists to address related operational costs. We view the expanded access program utilizing INOpulse treatment for COVID-19 patients as an important coal in the fire for reducing the burden of the ongoing pandemic, and we believe the INOpulse clinical program can continue its development in the interim.”Based on one additional Buy rating published over the last 3 months, Bellerophon has a Moderate Buy consensus rating. The average price target is, like Fein’s, $30. (See Bellerophon stock analysis on TipRanks) More recent articles from Smarter Analyst: * Risk-Takers Have a Reasonable Shot With American Airlines Stock * 3 'Safe Haven' Gold Stocks With at Least 15% Upside * Halliburton Incurs $1 Billion Quarterly Loss, Sees Spending Cuts Amid Oil Price Crisis * Pepsi Scores FTC Approval For $3.85 Billion Rockstar Deal
- 04/09/2020
|
Mesoblast's COVID-19 Foray, And Other News: The Good, Bad And Ugly Of Biopharma
- Mesoblast was up on an IND approval targeting COVID-19. Crinetics announced positive trial data. Bellerophon announced earnings and program updates.
- 04/08/2020
|
Bellerophon Therapeutics Submits Investigational New Drug Application to Study INOpulse® Inhaled Nitric Oxide Therapy for the Treatment of COVID-19
- Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to study the INOpulse® inhaled nitric oxide system (iNO) for the treatment of patients infected with COVID-19. INOpulse is the only therapy to deliver targeted nitric oxide by autonomously adjusting to the patient’s breathing pattern to ensure accurate and consistent drug delivery into the airways. The proposed randomized, open-label study, called PULSE-CVD19-001, will evaluate the efficacy and safety of INOpulse in patients with COVID-19 who require supplemental oxygen.
- 04/08/2020
|
Bellerophon Therapeutics: A Promising Solution To America's Ventilator Shortage During The COVID-19 Pandemic
- BLPH was granted Emergency Expanded Access for INOpulse® for the treatment of COVID-19. The first COVID-19 patient who was treated has been discharged from the
- 04/07/2020
|
Analysts Offer Insights on Healthcare Companies: Inovio Pharmaceuticals (NASDAQ: INO), Intercept Pharma (NASDAQ: ICPT) and Bellerophon (NASDAQ: BLPH)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inovio Pharmaceuticals (
INO
–
Research Report
), Intercept Pharma (
ICPT
–
Research Report
) and Bellerophon (
BLPH
–
Research Report
) with bullish senti
- 04/07/2020
|
Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2019 Financial Results
- WARREN, N.J., April 06, 2020 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary.
- 04/06/2020
|
An Unpredictable Market Demands Caution
- I hope everyone’s had a good and, more importantly, safe week. It’s been a tough time, and we’re still in early innings. But if we stay safe, observe the social...
- 04/03/2020
|
RDS.A, ARNC among top premarket gainers
- ION Geophysical (NYSE:IO) +120% on expecting big jump in Q1 revenues.Neptune Wellness Solutions (NASDAQ:NEPT) +47% on receiving health Canada authorization to commercialize natural, plant-based hand s
- 04/02/2020
|
30 Stocks Moving in Thursday's Pre-Market Session
- Gainers
ION Geophysical Corporation (NYSE: IO) shares rose 150% to $2.90 in pre-market trading after the company reported announces preliminary Q1 revenue in the range of $56...
- 04/02/2020
|
Bellerophon Announces Closing of $15.3 Million Registered Direct Offering of Common Stock
- Bellerophon currently intends to use the net proceeds from this offering for working capital, general corporate purposes, and other research and development efforts. The shares were offered by Bellerophon pursuant to a “shelf” registration statement on Form S-3 that was initially filed on June 25, 2018 and declared effective by the Securities and Exchange Commission (“SEC”) on July 6, 2018 and the prospectus contained therein (File No. 333-225878).
- 04/01/2020
|
Bellerophon Therapeutics to Host Investor Call and Webcast Today on INOpulse® for the Treatment of COVID-19
- Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, announced that it will host an investor conference call and webcast on the INOpulse® inhaled nitric oxide system (iNO) for the treatment of COVID-19 at 1:00 PM EDT. The event will feature a presentation by Fabian Tenenbaum, Chief Executive Officer of Bellerophon Therapeutics, and Hunter Gillies, M.D., Chief Medical Officer of Bellerophon Therapeutics, who will discuss the Company's emergency expanded access program for INOpulse® for COVID-19, through which the first patient initiated treatment. Bellerophon Therapeutics is currently developing INOpulse for multiple cardiopulmonary indications.
- 03/31/2020
|
Bellerophon Announces $15.3 Million Registered Direct Offering Priced At-the-Market
- H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to Bellerophon from this offering are expected to be $15.3 million, before deducting the placement agent’s fees and other offering expenses payable by Bellerophon. The Company intends to use the net proceeds from this offering for working capital, general corporate purposes, and other research and development efforts.
- 03/30/2020
|
ABT, DD among premarket gainers
- Plus Therapeutics. (NASDAQ:PSTV) +63% in-licenses novel oncology candidates.Bellerophon Therapeutics (NASDAQ:BLPH) +40% as first COVID-19 patient has been treated with the INOpulse inhaled nitric oxid
- 03/30/2020
|
Bellerophon Therapeutics Announces First Patient Treated with INOpulse® Inhaled Nitric Oxide Therapy for COVID-19
- Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that expanded access treatment with the INOpulse® inhaled nitric oxide system (iNO) was initiated for the first time in a patient with a diagnosis of the novel coronavirus disease (COVID-19) at the University of Miami School of Medicine. The treatment follows the recent decision by the U.S. Food and Drug Administration (FDA) to grant emergency expanded access that allows INOpulse to immediately be used for the treatment of COVID-19 under the care and supervision of their physician. “Based on previous studies that demonstrate the benefits of iNO in oxygenation and immune response, INOpulse has the potential to be used as a viable treatment option for COVID-19,” said the treating physician, Roger Alvarez, DO, MPH, Assistant Professor, University of Miami School of Medicine.
- 03/30/2020
|
Bellerophon Shares Jump On Covid-19 OK
- The company’s nitric oxide delivery system has been granted FDA approval for compassionate use Continue reading...
- 03/29/2020
|
Soaring demand for ventilators creates political tension, promises to ramp up manufacturing
- Ventilators have become one of the most politicized and in-demand medical supplies as the number of COVID-19 cases in the U.S. grows and hospitals prepare...
- 03/29/2020
|
Coronavirus Update - Some Stock Picks For The Pandemic
- There are so many coronavirus related plays right now. As the market is crashing (despite rebounding today), coronavirus stocks are hot. Here are a few examples from last Friday’s market close…
- 03/26/2020
|
The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 23.) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Bellerophon Therapeutics Inc (NASDAQ: BLPH) (follow-on rally from Friday's news of FDA authorization
- 03/24/2020
|
The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 23.)
Arcutis Biotherapeutics...
- 03/24/2020
|
Company News for Mar 23, 2020
- Companies In The News Are: BLPH, GNMK, WORK, SRNE
- 03/23/2020
|
105 Biggest Movers From Friday
- Gainers
Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) shares climbed 431% to close at $18.00 on Friday after the company reported that the FDA granted emergency expanded access...
- 03/23/2020
|
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 3.04%
- U.S. stocks lower at close of trade; Dow Jones Industrial Average down 3.04%
- 03/23/2020
|
3 Coronavirus Stocks with Over 60% Upside
- In the battle against the coronavirus, who will be able to defeat this formidable foe? In the three months since the onset of this public health crisis, names from all over the world have stepped up, hoping their approach will ultimately yield success. Those at the front lines currently represent the
- 03/22/2020
|
3 Coronavirus Stocks with Over 60% Upside
- In the battle against the coronavirus, who will be able to defeat this formidable foe? In the three months since the onset of this public health crisis,
- 03/22/2020
|
Mid-Afternoon Market Update: Dow Tumbles Over 600 Points; Bellerophon Therapeutics Shares Surge
- Toward the end of trading Friday, the Dow traded down 3.1% to 19,464.34 while the NASDAQ fell 2.01% to 7,007.15. The S&P also rose, gaining 3.07% to 2,335.31.
U.S. reported a...
- 03/20/2020
|
Mid-Day Market Update: Crude Oil Down Over 10%; GenMark Diagnostics Shares Spike Higher
- Midway through trading Friday, the Dow traded up 0.32% to 20151.35 while the NASDAQ rose 0.80% to 7,207.99. The S&P fell 0.31% to 2,401.89.
US reported a total of 14,000...
- 03/20/2020
|
70 Stocks Moving In Friday's Mid-Day Session
- Gainers
Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) shares jumped 549% to $22.00 after the company reported that the FDA granted emergency expanded access for INOpulse for the...
- 03/20/2020
|
Mid-Morning Market Update: Markets Mostly Higher; Hibbett Sports Reports Mixed Q4 Results
- Following the market opening Friday, the Dow traded up 0.44% to 20,175.19 while the NASDAQ rose 1.25% to 7,239.90. However, the S&P fell 0.11% to 2,407.60.
US reported a total...
- 03/20/2020
|
Biotech and hospitality stocks among premarket gainers
- Bellerophon Therapeutics (NASDAQ:BLPH) +472% on FDA nod for emergency use of INOpulse for Covid-19.Rand Capital (NASDAQ:RAND) +87% on its portfolio company developing automated test kits for detection
- 03/20/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) * Biomerica, Inc. (NASDAQ: BMRA) * Centogene NV (NASDAQ: CNTG) * Gilead Sciences, Inc. (NASDAQ: GILD) * Imara Inc (NASDAQ: IMRA) * Regeneron Pharmaceuticals
- 03/20/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 19.)
Biomerica, Inc. (NASDAQ...
- 03/20/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
- 03/19/2020
|
FDA OKs new use of Boehringer Ingelheim's Ofev
- Under Priority Review and Breakthrough Therapy status, the FDA approves privately held Boehringer Ingelheim's Ofev (nintedanib) oral capsules for the treatment of patients with chronic fibrosing (scar
- 03/09/2020
|
The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace
- Biotech stocks turned in a lackadaisical performance last week amid earnings releases by smid-cap stocks, a few clinical readouts and data presentations at conferences and a handful of FDA verdicts. Merck ...
- 02/23/2020
|
Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates
- It was a low-key week for the biotech sector with updates from just a few small biotech companies.
- 02/19/2020
|
The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 18) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Anavex ...
- 02/19/2020
|
Mid-Morning Market Update: Markets Open Lower; Apple To Miss Q2 Revenue Guidance
- Following the market opening Tuesday, the Dow traded down 0.34% to 29298.15 while the NASDAQ fell 0.10% to 9721.71. The S&P also fell, dropping 0.19% to 3,373.88.
Leading and...
- 02/18/2020
|
TSLA, KR among premarket gainers
- Bellerophon Therapeutics (NASDAQ:BLPH) +67% on positive top-line data from a recently completed acute, intra-patient, dose escalation, hemodynamics study of INOpulse for the treatment of Pulmonary Hyp
- 02/18/2020
|
Bellerophon Therapeutics Shares Rip Higher On Phase 2 Hypertension Study Results
- Shares of biotherapeutics company Bellerophon Therapeutics Inc (NASDAQ: BLPH) were more than doubling Tuesday following a positive clinical readout from the company....
- 02/18/2020
|
The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering
- The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex Life Sciences Corp (NASDAQ: AVXL ) ...
- 02/14/2020
|
The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) AbbVie Inc (NYSE: ABBV ) Agile Therapeutics Inc (NASDAQ: ...
- 02/13/2020
|
The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN ) ...
- 02/11/2020
|
